PDGFRA D842 Inhibitors
1 drugsAbout PDGFRA D842
PDGFRA D842 is a specific mutation within the platelet-derived growth factor receptor alpha (PDGFRA), a receptor tyrosine kinase crucial for cell growth and survival. The D842 mutation leads to constitutive receptor activation, driving uncontrolled cell proliferation and contributing to disease development.
PDGFRA D842's oncogenic potential makes it a therapeutic target, as its persistent signaling fuels tumor growth. Currently, there is no genetic evidence available for this target.
AYVAKIT (avapritinib) is the only FDA-approved drug targeting PDGFRA D842, with 6 indications. It is a small molecule drug developed by BLUEPRINT MEDICINES.
Top PDGFRA D842 Drugs
BLUEPRINT MEDICINES is the only company with an approved drug targeting PDGFRA D842.
The market is highly concentrated, suggesting high barriers to entry or limited perceived opportunity for competing therapies.
PDGFRA D842 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PDGFRA D842, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide differentiation and address resistance mechanisms.
PDGFRA D842 Clinical Trials 17 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PDGFRA D842. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 4 | 0 | 2 | 100% |
| Phase 2 | 8 | 1 | 0 | 7 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
PDGFRA D842 Drug Approval Timeline (2020 - 2020)
AYVAKIT was first approved in 2020 and most recently approved in 2020.
The approval timeline shows recent entry, indicating potential for further market penetration or emerging clinical data.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PDGFRA D842. A trial counts if an approved drug acting on PDGFRA D842 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.